Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

ClinicalTrials.gov ID: NCT04161885

Public ClinicalTrials.gov record NCT04161885. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia (AML) (VIALE-T)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when given as maintenance therapy following allogeneic stem cell transplantation (SCT). This study will have 2 parts: Part 1 (Dose Confirmation), which may include participants who are greater than or equal to 18 years old; Part 2 (Randomization) which may include participants who are greater than or equal to 12 years old. During Part 1, recommended Phase 3 dose of venetoclax in combination with azacitidine will be determined and during Part 2, the efficacy and safety of venetoclax with azacitidine (Part 2 Arm A) will be compared with BSC (Part 2 Arm B).

Study identification

NCT ID
NCT04161885
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
AbbVie
Industry
Enrollment
465 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 25, 2020
Primary completion
Sep 22, 2025
Completion
Sep 22, 2025
Last update posted
Jun 3, 2026

2020 – 2025

United States locations

U.S. sites
43
U.S. states
25
U.S. cities
37
Facility City State ZIP Site status
Arizona Oncology - Scottsdale - Cancer Transplant Institute /ID# 239711 Scottsdale Arizona 85258-4547
University of Arizona Cancer Center - Tucson /ID# 242507 Tucson Arizona 85724
University of Arkansas for Medical Sciences /ID# 239804 Little Rock Arkansas 72205
City of Hope /ID# 213681 Duarte California 91010
UCHSC Anschultz Cancer Pavilion /ID# 215618 Aurora Colorado 80045-2517
Colorado Blood Cancer Institute /ID# 215980 Denver Colorado 80218
Mayo Clinic Hospital Jacksonville /ID# 239710 Jacksonville Florida 32224
AdventHealth Medical Group Blood & Marrow Transplant at Orlando /ID# 213985 Orlando Florida 32804-5505
Ann & Robert H. Lurie Children's Hospital of Chicago /ID# 215840 Chicago Illinois 60611
The University of Chicago Medical Center /ID# 215616 Chicago Illinois 60637-1443
Loyola University Medical Ctr /ID# 215617 Maywood Illinois 60153
Indiana Blood & Marrow Transpl /ID# 215842 Indianapolis Indiana 46237
Duplicate_Ochsner Clinic Foundation-New Orleans /ID# 213834 New Orleans Louisiana 70121
University of Maryland, Baltimore /ID# 213855 Baltimore Maryland 21201
Massachusetts General Hospital /ID# 215765 Boston Massachusetts 02114
Karmanos Cancer Institute - Dresner Clinic /ID# 214581 Detroit Michigan 48201-2013
Masonic Cancer Center /ID# 239492 Minneapolis Minnesota 55455
Mayo Clinic - Rochester /ID# 214685 Rochester Minnesota 55905-0001
University of Mississippi Medical Center /ID# 239343 Jackson Mississippi 39216-4500
The John Theurer Cancer /ID# 215251 Hackensack New Jersey 07601
Roswell Park Cancer Institute /ID# 217857 Buffalo New York 14263
Columbia University Medical Center /ID# 240875 New York New York 10032-3729
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 240680 New York New York 10065-6007
Weill Cornell Medical College /ID# 214887 New York New York 10065
Montefiore Medical Center - Moses Campus /ID# 241669 The Bronx New York 10467
University of North Carolina /ID# 215814 Chapel Hill North Carolina 27514
Atrium Health Wake Forest Baptist Medical Center /ID# 239210 Winston-Salem North Carolina 27157
UC Health - Cincinnati /ID# 239263 Cincinnati Ohio 45267-2800
University Hospitals Cleveland Medical Center /ID# 239260 Cleveland Ohio 44106
University of Oklahoma, Stephenson Cancer Center /ID# 215611 Oklahoma City Oklahoma 73104-5418
Oregon Health and Science University /ID# 215874 Portland Oregon 97239
Penn State Hershey Medical Ctr /ID# 217120 Hershey Pennsylvania 17033-2360
Children's Hospital of Philadelphia - Main /ID# 215410 Philadelphia Pennsylvania 19104-4319
University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 214518 Philadelphia Pennsylvania 19104
Duplicate_Allegheny General Hospital /ID# 216756 Pittsburgh Pennsylvania 15212
UPMC Hillman Cancer Ctr /ID# 213715 Pittsburgh Pennsylvania 15232
TriStar Centennial Medical Center /ID# 218750 Nashville Tennessee 37203-1551
Texas Oncology - Medical City Dallas /ID# 216720 Dallas Texas 75230
Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 213735 Dallas Texas 75246-2003
Texas Transplant Institute /ID# 214691 San Antonio Texas 78229
Virginia Commonwealth University Medical Center Main Hospital /ID# 239203 Richmond Virginia 23219
Fred Hutchinson Cancer Research Center /ID# 214436 Seattle Washington 98109-1024
Univ of Wisconsin Hosp/Clinics /ID# 216096 Madison Wisconsin 53792-0001

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 122 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04161885, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 3, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04161885 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →